HK1123199A1 - Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers - Google Patents
Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkersInfo
- Publication number
- HK1123199A1 HK1123199A1 HK09100853.7A HK09100853A HK1123199A1 HK 1123199 A1 HK1123199 A1 HK 1123199A1 HK 09100853 A HK09100853 A HK 09100853A HK 1123199 A1 HK1123199 A1 HK 1123199A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mmp3
- ctx
- adalimumab
- biomarkers
- subjects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Sustainable Development (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73244405P | 2005-11-01 | 2005-11-01 | |
PCT/US2006/042564 WO2007089303A2 (en) | 2005-11-01 | 2006-10-31 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1123199A1 true HK1123199A1 (en) | 2009-06-12 |
Family
ID=38327823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100853.7A HK1123199A1 (en) | 2005-11-01 | 2009-01-29 | Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers |
Country Status (22)
Country | Link |
---|---|
US (2) | US7919264B2 (sl) |
EP (2) | EP2357479A1 (sl) |
JP (4) | JP5198277B2 (sl) |
KR (2) | KR20140012160A (sl) |
CN (2) | CN103336129A (sl) |
AU (1) | AU2006337105B2 (sl) |
BR (1) | BRPI0618085A2 (sl) |
CA (1) | CA2626804A1 (sl) |
DK (1) | DK1948235T3 (sl) |
ES (1) | ES2431643T3 (sl) |
HK (1) | HK1123199A1 (sl) |
HR (1) | HRP20131112T1 (sl) |
IL (2) | IL190964A0 (sl) |
NZ (3) | NZ595340A (sl) |
PL (1) | PL1948235T3 (sl) |
PT (1) | PT1948235E (sl) |
RS (1) | RS53055B (sl) |
RU (2) | RU2438704C2 (sl) |
SG (1) | SG169361A1 (sl) |
SI (1) | SI1948235T1 (sl) |
TW (2) | TWI424161B (sl) |
WO (1) | WO2007089303A2 (sl) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
NZ598346A (en) * | 2002-07-19 | 2013-10-25 | Abbvie Biotechnology Ltd | Treatment of tnf alpha related disorders |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
CA2903138A1 (en) | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
US8874477B2 (en) | 2005-10-04 | 2014-10-28 | Steven Mark Hoffberg | Multifactorial optimization system and method |
CA2626804A1 (en) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
KR20140071452A (ko) | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
EP2012586A4 (en) * | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
WO2008057240A2 (en) * | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
EP2165194A4 (en) * | 2007-05-31 | 2010-09-08 | Abbott Lab | BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
CN101802005B (zh) * | 2007-08-28 | 2015-09-16 | 艾伯维生物技术有限公司 | 包括关于阿达木单抗的结合蛋白质的组合物和方法 |
US9404932B2 (en) * | 2007-11-05 | 2016-08-02 | Nordic Bioscience A/S | Pathology biomarker assay |
TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
JP2011510267A (ja) * | 2008-01-03 | 2011-03-31 | アボツト・バイオテクノロジー・リミテツド | 乾癬の治療における化合物の長期的効力の予測 |
AU2009204863B2 (en) | 2008-01-15 | 2015-07-16 | AbbVie Deutschland GmbH & Co. KG | Powdered protein compositions and methods of making same |
WO2010077722A1 (en) * | 2008-12-30 | 2010-07-08 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis |
GB0902737D0 (en) * | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
US20100260940A1 (en) * | 2009-04-08 | 2010-10-14 | Mccown James Charles | System and method for depositing metallic coatings on substrates using removable masking materials |
US20120135005A1 (en) * | 2009-04-16 | 2012-05-31 | Harding Fiona A | ANTI-TNF-a ANTIBODIES AND THEIR USES |
KR101721906B1 (ko) | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | 자동 주입 장치 |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
KR20120105444A (ko) | 2009-10-15 | 2012-09-25 | 오클라호마 메디컬 리써치 화운데이션 | 염증성 질병의 활성 측정 및 모니터링을 위한 바이오마커 및 방법 |
US9082177B2 (en) * | 2009-11-25 | 2015-07-14 | Dental Imaging Technologies Corporation | Method for tracking X-ray markers in serial CT projection images |
NZ600069A (en) | 2009-12-15 | 2015-02-27 | Abbvie Biotechnology Ltd | Improved firing button for automatic injection device |
CA2796186C (en) | 2010-04-21 | 2019-04-09 | Abbott Biotechnology Ltd. | Wearable automatic injection device for controlled delivery of therapeutic agents |
US8747854B2 (en) | 2010-06-03 | 2014-06-10 | Abbvie Biotechnology Ltd. | Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies |
TWI606840B (zh) * | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
AU2012209223B2 (en) | 2011-01-24 | 2015-11-05 | Abbvie Biotechnology Ltd | Automatic injection devices having overmolded gripping surfaces |
KR102001050B1 (ko) | 2011-01-24 | 2019-07-17 | 엘캠 메디컬 애그리컬처럴 코오퍼레이티브 어소시에이션 리미티드 | 인젝터 |
MX350384B (es) | 2011-01-24 | 2017-09-04 | Abbvie Biotechnology Ltd | Separación de protectores de aguja de jeringas y dispositivos de inyección automáticos. |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US20150252422A1 (en) * | 2011-11-04 | 2015-09-10 | Sequenta Llc | T-cell receptor clonotypes shared among ankylosing spondylitis patients |
ES2683037T3 (es) | 2011-12-09 | 2018-09-24 | Adaptive Biotechnologies Corporation | Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
US20140052020A1 (en) * | 2012-08-15 | 2014-02-20 | University Of Florida Research Foundation, Inc. | Magnetic apparatus and methods of use |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
EP2970375A1 (en) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
AU2013384204B2 (en) | 2013-03-14 | 2017-03-16 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
CA2926588C (en) | 2013-10-16 | 2020-07-21 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3126846A4 (en) | 2014-04-02 | 2017-08-30 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
KR101598296B1 (ko) | 2014-04-29 | 2016-02-26 | 가톨릭대학교 산학협력단 | Dna 복제수 변이를 이용한 강직성 척추염 발병 고위험도 예측용 조성물 및 이를 이용한 예측 방법 |
CA2950771A1 (en) | 2014-06-10 | 2015-12-17 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity |
EP3160996B1 (en) * | 2014-06-30 | 2022-06-08 | Merck Patent GmbH | Anti-tnfa antibodies with ph-dependent antigen binding |
WO2016004197A1 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
US20160185848A1 (en) | 2014-07-09 | 2016-06-30 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using sugars |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
WO2017058999A2 (en) | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal |
WO2017059003A1 (en) | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing psoriatic arthritis disease activity |
WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
RU2714312C1 (ru) * | 2016-04-15 | 2020-02-14 | Есм Текнолоджис, Ллс | Способ оценки лекарственных средств для суставных хрящей |
CN106290885A (zh) * | 2016-07-18 | 2017-01-04 | 本·沙朗 | 一种血清英夫利西elisa检测试剂盒和检测方法 |
CN106501523A (zh) * | 2017-01-17 | 2017-03-15 | 安徽同致生物工程股份有限公司 | 基质蛋白酶3测定试剂盒 |
TWI671761B (zh) * | 2017-05-01 | 2019-09-11 | 臺中榮民總醫院 | 脊椎關節炎患者疾病活動度電子病歷管理系統 |
WO2019178546A1 (en) | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
CN108872585A (zh) * | 2018-05-08 | 2018-11-23 | 广州创尔生物技术股份有限公司 | 一种胶原蛋白端肽的检测方法 |
JP2022541125A (ja) | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
RU2724276C1 (ru) * | 2020-03-19 | 2020-06-22 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А. Насоновой" (ФГБНУ НИИР им. В.А. Насоновой) | Способ экспресс-оценки риска поражения осевого скелета при ранних формах псориатического артрита |
KR102573606B1 (ko) * | 2021-10-14 | 2023-08-31 | 계명대학교 산학협력단 | 혈청 시료를 이용하여 류마티스성 질환과 강직성 척추염을 구분하여 진단하기 위한 조성물 및 키트 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US6153732A (en) * | 1987-11-06 | 2000-11-28 | Washington Research Foundation | Kit for detecting analyte indicative of type II collagen resorption in vivo |
US5702909A (en) | 1987-11-06 | 1997-12-30 | Washington Research Foundation | Methods of detecting collagen type II degradation in vivo |
US5300434A (en) | 1987-11-06 | 1994-04-05 | Washington Research Foundation | Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6498237B2 (en) * | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
US5136248A (en) | 1990-01-29 | 1992-08-04 | Niagara Mohawk Power Corporation | Method and detector for identifying insulator flashover |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US20070298040A1 (en) * | 1991-03-18 | 2007-12-27 | Centocor, Inc. | Methods of treating seronegative arthropathy with anti-TNF antibodies |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
EP0679196B1 (en) | 1993-01-07 | 2004-05-26 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
EP0689610B1 (en) | 1993-03-19 | 2002-07-03 | Sequenom, Inc. | Dna sequencing by mass spectrometry via exonuclease degradation |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
GB9702252D0 (en) | 1997-02-06 | 1997-03-26 | Univ Sheffield Medical The Sch | Collagen assay |
US6506607B1 (en) | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
US6607879B1 (en) | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
US6642007B1 (en) * | 1998-11-02 | 2003-11-04 | Pfizer Inc. | Assays for measurement of type II collagen fragments in urine |
US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
EP1372720A4 (en) * | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
WO2002096461A1 (en) * | 2001-05-25 | 2002-12-05 | Abbott Gmbh & Co. Kg | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients |
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20090280065A1 (en) | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
NZ598346A (en) * | 2002-07-19 | 2013-10-25 | Abbvie Biotechnology Ltd | Treatment of tnf alpha related disorders |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
JP4500683B2 (ja) | 2002-11-01 | 2010-07-14 | バイエル・ヘルスケア・エルエルシー | 巨大分子濃縮方法 |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US20040203072A1 (en) | 2002-11-08 | 2004-10-14 | Barnes-Jewish Hospital | Uncoupled collagen synthesis and degradation assays |
CN1225479C (zh) * | 2002-12-23 | 2005-11-02 | 马菁 | 肿瘤坏死因子抗体,其制备方法以及药物组合物 |
CN1953768B (zh) | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | 抗-egfr抗体的高浓缩液体制剂 |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
WO2007011390A2 (en) | 2004-10-09 | 2007-01-25 | Government Of The United States As Represented By The Secretary Of The Army | Large-scale production of human serum butyrylcholinesterase as a bioscavenger |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
US7541028B2 (en) * | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for monoclonal antibody delivery |
US8349991B2 (en) | 2005-04-19 | 2013-01-08 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
CA2903138A1 (en) * | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
CA2626804A1 (en) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
US20070202051A1 (en) | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
KR20140071452A (ko) | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
EP2012586A4 (en) * | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
EP2007426A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
BRPI0716762A2 (pt) * | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
WO2008057240A2 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
EP2165194A4 (en) * | 2007-05-31 | 2010-09-08 | Abbott Lab | BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES |
WO2008150490A2 (en) | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
WO2008154543A2 (en) * | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
CN101802005B (zh) | 2007-08-28 | 2015-09-16 | 艾伯维生物技术有限公司 | 包括关于阿达木单抗的结合蛋白质的组合物和方法 |
US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
TWI661833B (zh) * | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
JP2011510267A (ja) * | 2008-01-03 | 2011-03-31 | アボツト・バイオテクノロジー・リミテツド | 乾癬の治療における化合物の長期的効力の予測 |
AU2009204863B2 (en) * | 2008-01-15 | 2015-07-16 | AbbVie Deutschland GmbH & Co. KG | Powdered protein compositions and methods of making same |
AU2009206089B2 (en) * | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
CN102282173A (zh) | 2008-03-24 | 2011-12-14 | 艾博特生物技术有限公司 | 用于治疗骨丢失的方法和组合物 |
US9094979B2 (en) | 2008-05-16 | 2015-07-28 | Qualcomm Incorporated | Load balancing in a wireless communication system |
KR101721906B1 (ko) | 2009-04-29 | 2017-03-31 | 애브비 바이오테크놀로지 리미티드 | 자동 주입 장치 |
JP2012526121A (ja) | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
CA2789168A1 (en) | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor |
US8747854B2 (en) | 2010-06-03 | 2014-06-10 | Abbvie Biotechnology Ltd. | Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies |
-
2006
- 2006-10-31 CA CA002626804A patent/CA2626804A1/en not_active Abandoned
- 2006-10-31 SI SI200631648T patent/SI1948235T1/sl unknown
- 2006-10-31 PT PT68498658T patent/PT1948235E/pt unknown
- 2006-10-31 WO PCT/US2006/042564 patent/WO2007089303A2/en active Application Filing
- 2006-10-31 SG SG201100668-1A patent/SG169361A1/en unknown
- 2006-10-31 EP EP11155169A patent/EP2357479A1/en not_active Withdrawn
- 2006-10-31 RU RU2008121880/15A patent/RU2438704C2/ru not_active IP Right Cessation
- 2006-10-31 EP EP06849865.8A patent/EP1948235B1/en active Active
- 2006-10-31 TW TW095140333A patent/TWI424161B/zh not_active IP Right Cessation
- 2006-10-31 PL PL06849865T patent/PL1948235T3/pl unknown
- 2006-10-31 NZ NZ595340A patent/NZ595340A/xx not_active IP Right Cessation
- 2006-10-31 CN CN201310240384XA patent/CN103336129A/zh active Pending
- 2006-10-31 BR BRPI0618085-0A patent/BRPI0618085A2/pt not_active IP Right Cessation
- 2006-10-31 TW TW102119988A patent/TW201337266A/zh unknown
- 2006-10-31 JP JP2008538977A patent/JP5198277B2/ja not_active Expired - Fee Related
- 2006-10-31 RS RS20130493A patent/RS53055B/en unknown
- 2006-10-31 NZ NZ567286A patent/NZ567286A/en not_active IP Right Cessation
- 2006-10-31 US US11/591,241 patent/US7919264B2/en active Active
- 2006-10-31 DK DK06849865.8T patent/DK1948235T3/da active
- 2006-10-31 AU AU2006337105A patent/AU2006337105B2/en not_active Ceased
- 2006-10-31 CN CN200680040803A patent/CN101663048A/zh active Pending
- 2006-10-31 ES ES06849865T patent/ES2431643T3/es active Active
- 2006-10-31 KR KR1020137031666A patent/KR20140012160A/ko active IP Right Grant
- 2006-10-31 NZ NZ608431A patent/NZ608431A/en not_active IP Right Cessation
-
2008
- 2008-04-17 IL IL190964A patent/IL190964A0/en unknown
- 2008-04-30 KR KR1020087010615A patent/KR101468523B1/ko not_active IP Right Cessation
-
2009
- 2009-01-29 HK HK09100853.7A patent/HK1123199A1/xx not_active IP Right Cessation
-
2011
- 2011-01-25 IL IL210876A patent/IL210876A0/en unknown
- 2011-02-25 US US13/034,809 patent/US9086418B2/en not_active Expired - Fee Related
- 2011-06-27 RU RU2011126441/15A patent/RU2011126441A/ru not_active Application Discontinuation
- 2011-11-17 JP JP2011251783A patent/JP2012093361A/ja not_active Ceased
-
2013
- 2013-07-29 JP JP2013156781A patent/JP2014013241A/ja not_active Ceased
- 2013-11-21 HR HRP20131112TT patent/HRP20131112T1/hr unknown
-
2014
- 2014-11-28 JP JP2014241725A patent/JP2015096856A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1123199A1 (en) | Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers | |
IL185547A0 (en) | Lipocalin protein | |
EP2021467A4 (en) | CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH | |
EP1871418A4 (en) | HUMANIZED ANTI-CD70 BINDING AGENTS AND USES THEREOF | |
IL198872A0 (en) | Igf-1r binding proteins and compositions containing the same | |
EP1909097A4 (en) | BIOSENSOR AND BIOSENSOR CELL | |
IL180852A0 (en) | Anti-cd154 antibodies | |
NO20081839L (no) | 5-lipoksygenase-aktiverende protein (FLAP) inhibitorer | |
IL189685A0 (en) | Compositions and methods for analyzing protein interactions | |
EP1914315A4 (en) | METHOD FOR DETERMINING A GLYCOSYLATED PROTEIN AND DETERMINING KIT | |
EP1845376A4 (en) | QUANTITATIVE MEASURING PROCEDURE FOR RECOMBINANT PROTEIN | |
GB0609612D0 (en) | Detection method and kit | |
DE602005027623D1 (de) | Kraftunterstützte probenwiedergewinnung in der gelelektrophorese | |
GB2443133B (en) | Analytical method and kit | |
HK1113405A1 (en) | Multifunctional reference system for use in analyte detection by fluorescence | |
EP1946261A4 (en) | PRESENTATION DOSSIERS FOR THE CREATION OF A DISK | |
GB0419059D0 (en) | Sediment assessment | |
GB2417480B (en) | Improvements in or relating to valves | |
GB2427637B (en) | Improvements in or relating to valves | |
GB0710515D0 (en) | Protein detection and quantitation using hydroxyquinolone dyes | |
GB0413142D0 (en) | Improvements in, or relating to testing | |
GB0522113D0 (en) | vWFA-domain containing proteins | |
GB2418496B (en) | Improvements in or relating to eyewear | |
GB0426940D0 (en) | Anti-freeze protein | |
GB0401882D0 (en) | Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171031 |